MODERN ASPECTS OF NEBULIZER THERAPY
https://doi.org/10.57256/2949-0715-2023-1-50-59
Abstract
Nebulizer therapy is widely used in modern respiratory medicine. Nebulizers are devices that convert a liquid into a suitable for inhalation by a patient aerosol, which meets the requirements of the European standard for nebulizer therapy prEN 13544-1. The fundamental differences between nebulizers and other inhalation devices (metered aerosol inhalers, powder inhalers) are the possibility to perform maneuvers on spontaneous breathing, the use of drugs, which do not involve the use of other inhalers, and the possibility to select drug doses depending on patients need.
Although this delivery method is effective for many respiratory diseases, and it is preferred for special groups (children, the elderly, as well as severe exacerbations, etc.), there are some peculiarities and limitations of its use, which should be taken into account by clinicians. According to the principle of operation, nebulizers are divided into compressor, ultrasonic and electronic-mesh, which differ in technical characteristics and indications for use. Compressor nebulizers are most widely used in medical institutions (intensive care units, hospitals, offices) and at home, relatively inexpensive, simple and easy to maintain, have additional components (chambers with inhalation-exhalation valves, masks for children and children) adults, nasal aspirator, etc.). Modern jet nebulizers are equipped with spray mode switches, so that the aerosol feed rate and the aerodynamic diameter of particles of an average mass from 2-3 to 10 microns can be adjusted. Depending on the selection of the switch mode and the corresponding medication, the nebulizer can be used in the treatment of rhinitis, laryngitis, bronchitis, asthma and other diseases of both upper and lower respiratory tract.
About the Author
Svetlana N. Buynova
ГБОУ ДПО ИГМАПО
Russian Federation
Russian Federation
Cand.Med.Sci., associated professor Department of Clinical Allergology and Pulmonology, Irkutsk State Medical Academy of Postgraduate Education – Branch of Russian Medical Academy of Continuing Professional Education
References
1. Geddes D. The history of respiratory disease management. Medicine (Abingdon). 2016;44(6):393-397. https://doi.org/10.1016/j.mpmed.2016.03.006
2. Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16(2):71-81. https://doi.org/10.3132/pcrj.2007.00017
3. Stein S.W., Thiel C.G. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20-41. https://doi.org/10.1089/jamp.2016.1297
4. Clark A.R. Medical aerosol inhaler: past, present, and future. Aerosol Sci Technol. 1995;22(4):374–391. https://doi.org/10.1080/02786829408959755
5. Nikander K., Sanders M. The early evolution of nebulizers. Medicamundi. 2010;54:47–53. URL: https://www.researchgate.net/publication/285935021_The_early_evolution_of_nebulizers [accessed: 21.11.2022]
6. Boe J., Dennis J.H., O'Driscoll B.R. et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18(1):228-242. https://doi.org/10.1183/09031936.01.00220001
7. Hess D.R. Nebulizers: principles and performance. Respir Care. 2000;45(6):609-622. URL: https://pubmed.ncbi.nlm.nih.gov/10894454/ [accessed: 21.11.2022]
8. Gardenhire D.S., Burnett D., Strickland S., Myers T.R. A Guide to Aerosol Delivery Devices for Respiratory Therapists. 4th ed. Irving, Texas:American Association for Respiratory Care;2017:64.
9. Braido F., Chrystyn H., Baiardini I. et al. "Trying, But Failing" - The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence. J Allergy Clin Immunol Pract. 2016;4(5):823-832. https://doi.org/10.1016/j.jaip.2016.03.002
10. Chandel A., Goyal A.K., Ghosh G., Rath G. Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019;112:108601. https://doi.org/10.1016/j.biopha.2019.108601
11. McGrath J.A., O'Sullivan A., Bennett G. et al. Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation. Pharmaceutics. 2019;11(2):75. https://doi.org/10.3390/pharmaceutics11020075
12. Hatley R.H., Byrne S.M. Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines sufficient to produce meaningful information?. Med Devices (Auckl). 2017;10:17-28. https://doi.org/10.2147/MDER.S125104
13. Posa D., Pizzulli A., Wagner P. et al. Efficacy and usability of a novel nebulizer targeting both upper and lower airways. Ital J Pediatr. 2017;43(1):89. https://doi.org/10.1186/s13052-017-0400-x
14. Skaria S., Smaldone G.C. Omron NE U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173-180. https://doi.org/10.1089/jamp.2010.0817
15. The use of ultrasonic and compressor inhalers (nebulizers) for the treatment of diseases of the respiratory tract and lungs. Ed. L.V. Osipov M.; 2014:132 (In Russian).
16. Geller D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50(10):1313-1322. URL: https://pubmed.ncbi.nlm.nih.gov/16185367/ [accessed: 21.11.2022]
17. Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371. https://doi.org/10.1378/chest.127.1.335
18. Everard M.L. Inhalation therapy for infants. Adv Drug Deliv Rev. 2003;55(7):869-878. https://doi.org/10.1016/s0169-409x(03)00082-6
19. Sturm R. Bioaerosols in the lungs of subjects with different ages-part 1: deposition modeling. Ann Transl Med. 2016;4(11):211. https://doi.org/10.21037/atm.2016.05.62
20. Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308-1331. https://doi.org/10.1183/09031936.00166410
21. Current inhalational devices for treatment of respiratory disease. Task Force report of European Respiratory Society and the International Societyfor Aerosols in Medicine. Pulmonologiya. 2011;(6):17-41 (In Russian). URL: https://journal.pulmonology.ru/pulm/article/view/414/413?locale=ru_RU [accessed: 21.11.2022]
22. Chuchalin A.G., Knyazheskaya N.P., Potapova M.O. The place of nebulizer therapy in the inhalation therapy of chronic obstructive pulmonary diseases. Russian medical journal. 2006;7:521-524 (In Russian). URL: https://www.rmj.ru/articles/obshchie-stati/Mesto_nebulayzerov_v_ingalyacionnoy_terapii_hronicheskih_obstruktivnyh_zabolevaniy_legkih/ [accessed: 21.11.2022]
23. Geppe N.A., Mokina N.A. Modern inhalation therapy: a practical guide for doctors. Moscow:GEOTAR-Media;2016:122 (In Russian).
24. Barta S.K., Crawford A., Roberts C.M. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med. 2002;96(6):375-381. https://doi.org/10.1053/rmed.2001.1292
25. Smaldone G.C., Cruz-Rivera M., Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. Journal of Aerosol Medicine. 1998;11(2):113–125. https://doi.org/10.1089/jam.1998.11.113
26. O'Doherty M.J., Miller R.F. Aerosols for therapy and diagnosis. Eur J Nucl Med. 1993;20(12):1201-1213. https://doi.org/10.1007/BF00171019
27. Kamin W., Erdnüss F., Krämer I. Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013. J Cyst Fibros. 2014;13(3):243-250. https://doi.org/10.1016/j.jcf.2013.09.006
28. Clinical guidelines: Acute respiratory viral infection (ARVI) (children). Union of Pediatricians of Russia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2022 (In Russian). URL: https://cr.minzdrav.gov.ru/schema/25_2 [accessed: 12.01.2023]
29. Albu S. Novel drug-delivery systems for patients with chronic rhinosinusitis. Drug Des Devel Ther. 2012;6:125-132. https://doi.org/10.2147/DDDT.S25199
30. Farzal Z., Basu S., Burke A. et al. Comparative study of simulated nebulized and spray particle deposition in chronic rhinosinusitis patients. Int Forum Allergy Rhinol. 2019;9(7):746-758. https://doi.org/10.1002/alr.22324
31. Macias-Valle L., Psaltis A.J. A Scholarly Review of the Safety and Efficacy of Intranasal Corticosteroids Preparations in the Treatment of Chronic Rhinosinusitis. Ear Nose Throat J. 2021;100(5):295-301. https://doi.org/10.1177/0145561320967727
32. Work group of the French Society of Otorhinolaryngology (SFORL). Consensus document for prescription of nebulization in rhinology. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):371-374. https://doi.org/10.1016/j.anorl.2014.07.004
33. Clinical guidelines: Acute obstructive laryngitis [croup] and epiglottitis (adults, children). Russian Union of Pediatricians, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, National Medical Association of Otorhinolaryngologists. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation 2021 (In Russian). URL: https://cr.minzdrav.gov.ru/schema/352_2 [accessed: 12.01.2023]
34. Johnson D.W. Croup. BMJ Clin Evid. 2014;2014:0321. URL: https://pubmed.ncbi.nlm.nih.gov/25263284/ [accessed: 12.01.2023]
35. Clinical guidelines: Bronchitis (children). Russian Union of Pediatricians, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, Russian Respiratory Society. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation 2021 (In Russian). URL: https://cr.minzdrav.gov.ru/schema/381_2 [accessed: 12.01.2023]
36. Clinical guidelines: Bronchial asthma (adults, children) // Russian Respiratory Society, Russian Association of Allergists and Clinical Immunologists, Russian Union of Pediatricians. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation 2021. (In Russian). URL: https://cr.minzdrav.gov.ru/schema/359_2 [accessed: 12.01.2023]
37. Camargo C.A. Jr., Ramachandran S., Ryskina K.L., Lewis B.E., Legorreta A.P. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm. 2007;64(10):1054-1061. https://doi.org/10.2146/ajhp060256
38. McLaughlin T., Leibman C., Patel P., Camargo C.A. Jr. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr Med Res Opin. 2007;23(6):1319-1328. https://doi.org/10.1185/030079907X188170
39. Melani A.S. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care. 2012;57(7):1161-1174. https://doi.org/10.4187/respcare.01414
40. Knightly R., Milan S.J., Hughes R. et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2017;11(11):CD003898. https://doi.org/10.1002/14651858.CD003898.pub6
41. Clinical guidelines: Cystic fibrosis (cystic fibrosis) (adults, children). Union of Pediatricians of Russia, Association of Medical Genetics, Russian Respiratory Society, Russian Transplant Society, Association of Children's Doctors of the Moscow Region. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2021 (In Russian). URL: https://cr.minzdrav.gov.ru/schema/372_2 [accessed: 12.01.2023]
42. Clinical guidelines: Chronic obstructive pulmonary disease. Interregional public organization "Russian Respiratory Society". Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation 2021 (In Russian). URL: https://cr.minzdrav.gov.ru/recomend/603_2 [accessed: 12.01.2023]
43. Brocklebank D., Ram F., Wright J. et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1-149. https://doi.org/10.3310/hta5260.
44. Rogliani P., Calzetta L., Coppola A. et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017;124:6-14. https://doi.org/10.1016/j.rmed.2017.01.006
45. Tashkin D.P. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585-2596. https://doi.org/10.2147/COPD.S114034
46. Sturm R. Bioaerosols in the lungs of subjects with different ages-part 1: deposition modeling. Ann Transl Med. 2016;4(11):211. https://doi.org/10.21037/atm.2016.05.62
47. Kishida M., Suzuki I., Kabayama H. et al. Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma. J Asthma. 2002;39(4):337-339. https://doi.org/10.1081/jas-120002291
48. Biddiscombe M.F., Usmani O.S. Is there room for further innovation in inhaled therapy for airways disease?. Breathe (Sheff). 2018;14(3):216-224. https://doi.org/10.1183/20734735.020318
49. Hickey A.J. Emerging trends in inhaled drug delivery. Adv Drug Deliv Rev. 2020;157:63-70. https://doi.org/10.1016/j.addr.2020.07.006
Supplementary files
Review
For citations:
Buynova S.N. MODERN ASPECTS OF NEBULIZER THERAPY. Baikal Medical Journal. 2023;2(1):50-59. (In Russ.) https://doi.org/10.57256/2949-0715-2023-1-50-59
Views:
2475
